Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Capecitabine
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 May 2016 Status changed from active, no longer recruiting to completed.
- 25 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed to 1 Aug 2017.
- 25 Jun 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.